{
    "clinical_study": {
        "@rank": "27017", 
        "acronym": "22-00", 
        "arm_group": [
            {
                "arm_group_label": "Induction chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Approved induction CT regimen after randomization."
            }, 
            {
                "arm_group_label": "Induction chemotherapy followed by CM maintenance", 
                "arm_group_type": "Experimental", 
                "description": "Approved induction chemotherapy followed by 12 months of CM maintenance."
            }
        ], 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. It is not yet known which combination chemotherapy regimen is\n      more effective after surgery in treating breast cancer.\n\n      PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens\n      in treating patients who have stage I, stage II, or stage III breast cancer."
        }, 
        "brief_title": "Combination Chemotherapy After Surgery in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the efficacy of adjuvant induction chemotherapy with or without\n           cyclophosphamide and methotrexate as maintenance chemotherapy in patients with stage I,\n           II, or III breast cancer.\n\n        -  Compare the disease-free survival, overall survival, and systemic disease-free survival\n           of patients treated with these regimens.\n\n        -  Compare the toxic effects of these regimens in these patients.\n\n        -  Compare the quality of life of patients treated with these regimens.\n\n      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified\n      according to participating center, menopausal status (pre vs post), and approved induction\n      chemotherapy (doxorubicin and cyclophosphamide vs other agents). Patients are randomized to\n      one of two treatment arms.\n\n        -  Arm I: Patients receive one of the following approved adjuvant induction chemotherapy\n           regimens:\n\n             -  AC comprising doxorubicin and cyclophosphamide IV on day 1 every 21 days for 4\n                courses followed by paclitaxel IV or docetaxel IV on day 1 every 21 days for 4\n                courses\n\n             -  EC comprising epirubicin and cyclophosphamide IV on day 1 every 21 days for 4\n                courses followed by paclitaxel IV or docetaxel IV on day 1 every 21 days for 4\n                courses\n\n             -  FAC comprising cyclophosphamide, doxorubicin, and fluorouracil IV on days 1 every\n                21 days for 4 courses\n\n             -  Doxorubicin every 21 days for 4 courses followed by CMF comprising\n                cyclophosphamide IV, methotrexate IV, and fluorouracil IV on days 1 and 8 every 28\n                days for 4 courses\n\n             -  AC OR EC and paclitaxel IV with filgrastim (G-CSF) every 14 days for 4 courses\n\n             -  FEC comprising cyclophosphamide IV, epirubicin IV and fluorouracil IV on day 1\n                every 21 days for 3 courses followed by docetaxel IV on day 1 every 21 days for 3\n                courses\n\n             -  TAC comprising docetaxel, doxorubicin, and cyclophosphamide IV on day 1 every 21\n                days for 6 courses\n\n             -  AT comprising doxorubicin IV and docetaxel IV every 21 days for 3 courses followed\n                by CMF for 3 courses\n\n        -  Arm II: Patients receive adjuvant induction chemotherapy as in arm I. Beginning within\n           56 days after the first day of the last course of induction chemotherapy, patients\n           receive CM (maintenance chemotherapy) comprising oral cyclophosphamide once daily and\n           oral methotrexate two times a day twice weekly for 1 year.\n\n      Patients with breast-conserving surgery receive radiotherapy following completion of\n      induction chemotherapy.\n\n      Patients with HER2-positive primary breast cancer may also receive trastuzumab (Herceptin)\n      during or following induction, and/or during and following CM.\n\n      Quality of life is assessed at baseline, at the beginning of each course of induction\n      chemotherapy, and at months 9, 12, 18, and 24.\n\n      Patients are followed every 6 months for 5 years and then annually thereafter.\n\n      PROJECTED ACCRUAL: Approximately 900 patients will be accrued for this study within 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed stage I, II, or III breast cancer\n\n               -  T1-3, N0-2, M0\n\n                    -  Patients with sentinel node biopsy positive disease must have undergone\n                       axillary dissection\n\n                    -  Tumor must be confined to the breast without detected metastases elsewhere\n\n               -  T4 disease with minimal dermal invasion allowed\n\n               -  No T4 disease with ulceration of skin, infiltration of skin (except\n                  pathologically minimal dermal involvement), peau d'orange, or inflammatory\n                  breast cancer\n\n          -  No bilateral breast cancer (except in situ carcinoma) or suspicious mass in opposite\n             breast that has not been proven benign\n\n          -  No distant metastases\n\n               -  No skeletal pain of unknown cause, elevated alkaline phosphatase, or bone scan\n                  showing hot spots that cannot be ruled out as metastases by x-ray, MRI, and/or\n                  CT\n\n          -  Must have undergone prior total mastectomy OR breast-conserving procedure (e.g.,\n             lumpectomy, quadrantectomy, or partial mastectomy with negative margins)\n\n               -  Patients must begin or have begun induction chemotherapy within 8 weeks after\n                  definitive surgery\n\n          -  Negative surgical margins\n\n          -  Axillary clearance with at least 6 lymph nodes examined OR\n\n          -  Negative sentinel node biopsy OR\n\n          -  Positive lymph nodes and unsuitable for taxane-based chemotherapy\n\n          -  Known HER2 status by immunohistochemistry or fluorescence in situ hybridization\n\n          -  Hormone receptor status:\n\n               -  Estrogen and progesterone receptor negative\n\n                    -  Less than 10% positive tumor cells by immunohistochemistry\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Sex:\n\n          -  Not specified\n\n        Menopausal status:\n\n          -  Premenopausal, defined as less than 6 months since last menstrual period (LMP) AND no\n             prior bilateral ovariectomy AND not on estrogen replacement (OR under age 50) OR\n\n          -  Postmenopausal, defined as prior bilateral ovariectomy OR more than 12 months since\n             LMP without prior hysterectomy (OR age 50 and over)\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  WBC greater than 3,000/mm3\n\n          -  Platelet count greater than 100,000/mm3\n\n        Hepatic:\n\n          -  See Disease Characteristics\n\n          -  Bilirubin less than 2.0 mg/dL\n\n          -  ALT less than 1.5 times upper limit of normal OR\n\n          -  AST less than 60 IU/L\n\n        Renal:\n\n          -  Creatinine less than 1.2 mg/dL\n\n        Other:\n\n          -  Not pregnant or lactating within the past 6 months\n\n          -  Fertile patients must use effective barrier contraception\n\n          -  No other prior or concurrent malignancy except adequately treated basal or squamous\n             cell carcinoma of the skin, carcinoma in situ of the cervix, or contralateral or\n             ipsilateral in situ breast carcinoma\n\n          -  No psychiatric or addictive disorders that would preclude study\n\n          -  No non-malignant systemic disease that would preclude study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior trastuzumab (Herceptin) allowed\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n          -  No prior adjuvant or neoadjuvant chemotherapy for breast cancer\n\n        Endocrine therapy:\n\n          -  No prior endocrine therapy for breast cancer or prevention\n\n          -  No prior tamoxifen or raloxifene for breast cancer\n\n        Radiotherapy:\n\n          -  No prior radiotherapy for breast cancer except primary irradiation\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No prior preventative therapy for breast cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "1080", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 10, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00022516", 
            "org_study_id": "CDR0000068827", 
            "secondary_id": [
                "IBCSG-22-00", 
                "EU-20119", 
                "EUDRACT-2005-005666-36"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "CAF regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "CMF regimen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "doxorubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "epirubicin hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Induction chemotherapy", 
                    "Induction chemotherapy followed by CM maintenance"
                ], 
                "intervention_name": "adjuvant therapy", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fluorouracil", 
                "Methotrexate", 
                "Doxorubicin", 
                "Epirubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "stage IA breast cancer", 
            "stage II breast cancer", 
            "stage IIIA breast cancer", 
            "stage IIIB breast cancer", 
            "stage IB breast cancer", 
            "estrogen receptor-negative breast cancer", 
            "progesterone receptor-negative breast cancer"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/IBCSG-22-00"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tweed Heads", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2485"
                    }, 
                    "name": "Tweed Heads Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5011"
                    }, 
                    "name": "Queen Elizabeth Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Box Hill", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3128"
                    }, 
                    "name": "Box Hill Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "East Ringwood", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3135"
                    }, 
                    "name": "Maroondah Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wodonga", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3690"
                    }, 
                    "name": "Murray Valley Private Hospital and Cancer Treatment Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "Australia", 
                        "zip": "1"
                    }, 
                    "name": "Christchurch Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "B-4000"
                    }, 
                    "name": "CHU Liege - Domaine Universitaire du Sart Tilman"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil", 
                        "state": "Rio Grande do Sul", 
                        "zip": "90035-003"
                    }, 
                    "name": "Hospital de Clinicas de Porto Alegre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Centro de Estudios Oncologicos Santiago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile", 
                        "zip": "29"
                    }, 
                    "name": "Fundacion Arturo Lopez Perez"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Hospital Clinico Universidad de Chile"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago", 
                        "country": "Chile"
                    }, 
                    "name": "Hospital Clinico San Borja Arriaran"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valparaiso", 
                        "country": "Chile"
                    }, 
                    "name": "Hospital Carlos Van Buren"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary", 
                        "zip": "1122"
                    }, 
                    "name": "National Institute of Oncology - Budapest"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergamo", 
                        "country": "Italy", 
                        "zip": "24100"
                    }, 
                    "name": "Ospedali Riuniti di Bergamo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Biella", 
                        "country": "Italy", 
                        "zip": "13900"
                    }, 
                    "name": "Ospedale degli Infermi - ASL 12"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carpi", 
                        "country": "Italy", 
                        "zip": "41012"
                    }, 
                    "name": "Ospedale Civile Ramazzini"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lecco", 
                        "country": "Italy", 
                        "zip": "23900"
                    }, 
                    "name": "Ospedale Alessandro Manzoni"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milan", 
                        "country": "Italy", 
                        "zip": "20142"
                    }, 
                    "name": "Ospedale San Paolo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20141"
                    }, 
                    "name": "European Institute of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "zip": "35128"
                    }, 
                    "name": "Azienda Ospedaliera di Padova"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rimini", 
                        "country": "Italy", 
                        "zip": "47900"
                    }, 
                    "name": "Ospedale Civile Rimini"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy", 
                        "zip": "00144"
                    }, 
                    "name": "Ospedale Sant' Eugenio"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy", 
                        "zip": "33100"
                    }, 
                    "name": "Policlinico Universitario Udine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibadan", 
                        "country": "Nigeria"
                    }, 
                    "name": "University of Ibadan Health Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru", 
                        "zip": "34"
                    }, 
                    "name": "Instituto Nacional de Enfermedades Neoplasicas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cluj-Napoca", 
                        "country": "Romania", 
                        "zip": "3400"
                    }, 
                    "name": "Institutul Oncologic - Universitatea de Medicina"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa", 
                        "zip": "2121"
                    }, 
                    "name": "Sandton Oncology Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aarau", 
                        "country": "Switzerland", 
                        "zip": "CH-5001"
                    }, 
                    "name": "Kantonsspital Aarau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bellinzona", 
                        "country": "Switzerland", 
                        "zip": "CH-6500"
                    }, 
                    "name": "Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bern", 
                        "country": "Switzerland", 
                        "zip": "CH-3010"
                    }, 
                    "name": "Inselspital Bern"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chur", 
                        "country": "Switzerland", 
                        "zip": "CH-7000"
                    }, 
                    "name": "Kantonsspital Graubuenden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rheinfelden", 
                        "country": "Switzerland", 
                        "zip": "4310"
                    }, 
                    "name": "FMH Onkologie/Haematologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "CH-9007"
                    }, 
                    "name": "Kantonsspital - St. Gallen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Thun", 
                        "country": "Switzerland", 
                        "zip": "3600"
                    }, 
                    "name": "Regionalspital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "CH-8091"
                    }, 
                    "name": "UniversitaetsSpital Zuerich"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Brazil", 
                "Chile", 
                "Hungary", 
                "Italy", 
                "Nigeria", 
                "Peru", 
                "Romania", 
                "South Africa", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Low-dose Cytotoxics as \"Anti-angiogenesis Treatment\" Following Adjuvant Induction Chemotherapy for Patients With ER-negative and PgR-negative Breast Cancer", 
        "overall_official": {
            "affiliation": "European Institute of Oncology", 
            "last_name": "Marco Colleoni, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Switzerland: Swissmedic", 
                "Romania: National Medicines Agency", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Nigeria: The National Agency for Food and Drug Administration and Control", 
                "Italy: The Italian Medicines Agency", 
                "Sweden: Medical Products Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease-free survival", 
            "safety_issue": "No", 
            "time_frame": "Estimated 10 years after last patient in"
        }, 
        "removed_countries": {
            "country": [
                "Spain", 
                "Sweden", 
                "Finland", 
                "Austria", 
                "Canada", 
                "New Zealand", 
                "Russian Federation", 
                "Singapore", 
                "Slovenia", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00022516"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival and systemic disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "Estimated 10 years after last patient in"
            }, 
            {
                "measure": "Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "Two years after randomization"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Estimated 10 years after last patient in"
            }
        ], 
        "source": "International Breast Cancer Study Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International Breast Cancer Study Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }, 
    "geocoordinates": {
        "Azienda Ospedaliera di Padova": "45.41 11.877", 
        "Box Hill Hospital": "-37.819 145.124", 
        "CHU Liege - Domaine Universitaire du Sart Tilman": "50.633 5.58", 
        "Centro de Estudios Oncologicos Santiago": "-33.417 -70.55", 
        "Christchurch Hospital": "-43.532 172.636", 
        "European Institute of Oncology": "45.464 9.188", 
        "FMH Onkologie/Haematologie": "47.552 7.793", 
        "Fundacion Arturo Lopez Perez": "-33.417 -70.55", 
        "Hospital Carlos Van Buren": "-33.046 -71.62", 
        "Hospital Clinico San Borja Arriaran": "-33.417 -70.55", 
        "Hospital Clinico Universidad de Chile": "-33.417 -70.55", 
        "Hospital de Clinicas de Porto Alegre": "-30.028 -51.229", 
        "Inselspital Bern": "46.948 7.445", 
        "Instituto Nacional de Enfermedades Neoplasicas": "-12.093 -77.046", 
        "Institutul Oncologic - Universitatea de Medicina": "46.777 23.6", 
        "Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni": "46.198 9.027", 
        "Kantonsspital - St. Gallen": "47.424 9.371", 
        "Kantonsspital Aarau": "47.391 8.046", 
        "Kantonsspital Graubuenden": "46.857 9.527", 
        "Maroondah Hospital": "-37.814 145.227", 
        "Murray Valley Private Hospital and Cancer Treatment Centre": "-36.122 146.888", 
        "National Institute of Oncology - Budapest": "47.498 19.041", 
        "Ospedale Alessandro Manzoni": "45.853 9.39", 
        "Ospedale Civile Ramazzini": "44.783 10.885", 
        "Ospedale Civile Rimini": "44.061 12.566", 
        "Ospedale San Paolo": "45.464 9.188", 
        "Ospedale Sant' Eugenio": "41.891 12.494", 
        "Ospedale degli Infermi - ASL 12": "45.563 8.058", 
        "Ospedali Riuniti di Bergamo": "45.695 9.67", 
        "Policlinico Universitario Udine": "46.065 13.231", 
        "Queen Elizabeth Hospital": "-34.929 138.6", 
        "Regionalspital": "46.748 7.626", 
        "Sandton Oncology Centre": "-26.204 28.047", 
        "Tweed Heads Hospital": "-28.174 153.543", 
        "UniversitaetsSpital Zuerich": "47.369 8.539", 
        "University of Ibadan Health Center": "7.396 3.917"
    }
}